| APL-1202是全球首个非肌层浸润型膀胱癌口服用药，有望极大减轻复发患者接受治疗的痛苦，是目前全球膀胱癌症治疗领域的一项重大突破。 |
APL-1202 注册临床招募： APL-1202 临床治疗非肌层浸润性膀胱癌，属于国家十二五重大新药专项产品。临床治疗经II期临床研究表明其疗效显著、安全性好、且口服给药，颠覆传统的化疗灌注治疗方式，使得癌症治疗不再痛苦。 我们的注册临床研究已经正式启动，如果您感兴趣欢迎您进一步了解相关内容。 |
||||
| - 待满足的市场需求 - 产品的巨大价值 - 临床研究进展 |
 |
||||
| |
We have established our unique Research and Development Strategy with below advantages: |
 |
|
| - Superior Human Safety - Reduced Development Risk - Shorter R&D Cycle |
| APL-1202 is the first oral drug in the world for the treatment of non-muscle-invasive bladder cancer (NMIBC), it is recognized as a breakthrough in bladder cancer therapy to relieve the pain of relapsed patients with superior efficacy. |
Patients Recruitment for APL-1202 Pivotal Trial |
||||
| - Unmet Medical Needs - Great Clinical Advantages - Clinical Development Update |
 |
||||
